WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008

Vaccine

Volumn 27, Issue 45, 2009, Pages 6366-6369

  Bright, Rick A ^a   Neuzil, Kathleen M ^b   Pervikov, Yuri ^c   Palkonyay, Laszlo ^c  

^a PATH   (United States)

^b PATH   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS SIALIDASE;

CONFERENCE PAPER; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNITY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS A H5N1; PORTUGAL; PRIORITY JOURNAL; STANDARDIZATION; VIRUS IMMUNITY; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; PORTUGAL; VIRAL PROTEINS; WORLD HEALTH ORGANIZATION;

EID: 70349974059     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.084     Document Type: Conference Paper

References (23)

1. Cassetti M., Couch R., Wood J., and Pervikov Y. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses. World Health Organization, Geneva, Switzerland, February 26-27, 2004. Vaccine 23 13 (2005) 1529-1533
2. Eichelberger M., Golding H., Hess M., Weir J., Subbarao K., Luke C., et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26 34 (2008) 4299-4303
3. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., and Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4 2 (2007) e59
4. Kilbourne E. Influenza. New York: Plenum Medical Book Co.; 1987.
5. Neumann G., and Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis 12 6 (2006) 881-886
6. Kilbourne E.D., Cerini C.P., Khan M.W., Mitchell Jr. J.W., and Ogra P.L. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccines. J Immunol 138 9 (1987) 3010-3013
7. Brett I.C., and Johansson B.E. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 339 2 (2005) 273-280
8. Couch R.B., and Kasel J.A. Immunity to influenza in man. Annu Rev Microbiol 37 (1983) 2845-2850
9. Palese P., Tobita K., Ueda M., and Compans R.W. Characterization of temperature-sensitive influenza virus mutants defective in neuraminidase. Virology 61 (1974) 397-410
10. Gottschalk A. Neuraminidase: the specific enzyme of influenza virus and Vibrio cholerae. Biochim Biophys Acta 23 3 (1957) 645-646
11. Choppin P., and Tamm I. Studies of two kinds of virus particles which comprise influenza A2 virus strains. II. Reactivity with virus inhibitors in normal sera. J Exp Med 112 (1960) 921-944
12. Schiff G, Kilbourne E, Smith G, Hackett C, Manoff S, Matthews J. Phase 2 clinical evaluation of an influenza A virus recombinant N2 neuraminidase. The First European influenza congress Hersonessos, Crete, Greece, September 23-28, 2000.
13. Johansson B.E., and Kilbourne E.D. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology 225 1 (1996) 136-144
14. Kilbourne E.D. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J Infect Dis 134 4 (1976) 384-394
15. Kilbourne E.D., Laver W.G., Schulman J.L., and Webster R.G. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 2 4 (1968) 281-288
16. Johansson B.E., Moran T.M., Bona C.A., Popple S.W., and Kilbourne E.D. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J Immunol 139 6 (1987) 2010-2014
17. Johansson B.E., Moran T.M., and Kilbourne E.D. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci USA 84 19 (1987) 6869-6873
18. Hocart M., Grajower B., Donabedian A., Pokorny B., Whitaker C., and Kilbourne E.D. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine 13 18 (1995) 1793-1798
19. Aminoff D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J 81 (1961) 384-392
20. Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem 234 8 (1959) 1971-1975
21. Powers D.C., Kilbourne E.D., and Johansson B.E. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol 3 5 (1996) 511-516
22. Lambre C.R., Terzidis H., Greffard A., and Webster R.G. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Meth 135 (1990) 49-57
23. Williams T.L., Luna L., Guo Z., Cox N., Pirkle J., Donis R., et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 26 20 (2008) 2510-2520